Epithelial-myoepithelial carcinoma (EMC) is a rare but aggressive tumor type that arises from epithelial and myoepithelial tissue. This disease mainly affects the salivary glands, but other localizations are also possible, such as the mammary glands and lungs. EMC is characterized by the presence of atypical cells that have a high potential for invasion and metastasis. This disease is most often observed in middle-aged women, but it can also be diagnosed in men and at a younger age. The tumor can manifest as a painless formation, which complicates early diagnosis and adequate therapy. The need for EMC examination is due to both clinical and pathomorphological aspects, which require more detailed study.
History of the disease and interesting historical facts
The first classification of salivary gland tumors, including epithelial-myoepithelial carcinoma, was proposed in the mid-20th century. For a long time, EMC remained poorly studied, which complicated diagnosis and treatment choices. The main research efforts were focused on more common forms of cancer, such as adenocarcinoma and squamous cell carcinoma. In the 1980s, clinical cases began to appear in the scientific literature, which made it possible to identify key characteristics of this type of tumor. Advances in molecular biology in the late 20th century contributed to an understanding of the genetic aspects of EMC occurrence. However, this type of carcinoma still remains on the periphery of scientific research, which affects the quality of diagnosis and treatment.
Epidemiology
Epithelial-myoepithelial carcinoma is currently considered a rare disease. Studies show that there are approximately 0.5-1 cases per 100,000 people per year. A distinctive feature of EMC is its prevalence among women, which may be due to hormonal factors. According to recent epidemiological studies, EMC accounts for less than 10% of all cases of salivary gland cancer. The influence of race and genetic predisposition on the incidence also requires further study. According to statistics, in the early stages, this disease is significantly more often diagnosed in older people, which implies the presence of concomitant risk factors, such as chronic diseases.
Genetic predisposition to this disease
Genetic studies have identified a number of mutations associated with EMC, but a definitive understanding of the genetic nature of this disease has not yet been achieved. In particular, changes have been identified in the TP53 genes, which play a key role in cell cycle control and apoptosis. Also involved in the study are genes such as MYB and GRM8, changes in which can lead to disruption of the normal regulation of cell growth and differentiation. Further studies are needed to determine the relationship between these mutations and clinical indicators, as well as to assess the role of heredity in the development of EMC.
Risk factors for the development of this disease
Risk factors that contribute to the development of epithelial-myoepithelial carcinoma can be divided into several categories:
- Physical factors: long-term exposure to radiation, which can increase the likelihood of mutations in cells.
- Chemical factors: contact with carcinogens such as formaldehyde and arsenic, which can cause changes in cellular DNA.
- Other factors: Having chronic inflammatory diseases of the salivary glands, such as sarcoidosis or Graves' disease, may also increase the risk of developing EMC.
It is important to note that many of the above risk factors may interact with each other, which complicates understanding the pathogenesis of the disease.
Diagnosis of this disease
Diagnosis of epithelial-myoepithelial carcinoma includes several key methods:
- Main symptoms: a painless growth in the area of the salivary glands, sometimes accompanied by swelling and discomfort.
- Laboratory research: blood tests for biomarkers that may indicate the presence of a tumor process.
- Radiological examinations: Ultrasound and MRI allow us to assess the size of the tumor and its spread.
- Other types of disease diagnostics: tissue biopsy sample for morphological examination of atypical cells.
- Differential diagnosis: Other neoplastic entities such as adenocarcinoma and benign tumors must be excluded.
An accurate diagnosis can only be made on the basis of a comprehensive approach and a combination of data from various methods.
Treatment
Treatment of epithelial-myoepithelial carcinoma includes several approaches:
- General treatment: strategic choice between surgical and adjuvant treatment depending on the stage of the disease.
- Pharmacological treatment: the use of chemotherapeutic drugs aimed at destroying abnormal cells.
- Surgical treatment: Radical tumor resection is the main treatment method for EMC.
- Other types of treatment: Radiation therapy may be recommended in cases where surgery is not possible.
The choice of treatment method depends on many factors, including the stage of the disease and the general condition of the patient.
List of medications used to treat this disease
Drugs used to treat epithelial-myoepithelial carcinoma include:
- Cisplatin
- Doxorubicin
- Taxanes
- Fluorouracil
- Transfusions of anti-cancer antibodies
The correct choice of drug therapy can significantly affect the quality of life and prognosis of the disease.
Disease monitoring
Monitoring the patient's condition is important to prevent relapses and complications.
- Control stages: regular check-ups with an oncologist, including clinical examination and imaging techniques.
- Forecast: With early diagnosis and adequate treatment, 5-year survival may exceed 70%.
- Complications: relapses, metastases to regional lymph nodes and distant organs are possible.
Creating a monitoring plan helps reduce the risk of negative outcomes.
Age-related features of the disease
Epithelial-myoepithelial carcinoma manifests itself differently in different age groups:
- In children: This disease is extremely rare and symptoms may be less severe.
- In young people: there is a high risk of aggressive course and metastasis.
- In older people: concomitant pathology occurs more frequently, which complicates treatment methods.
At every stage of life, a differentiated approach to diagnosis and treatment is important.
Questions and Answers
- What is epithelial myoepithelial carcinoma? This is a rare type of cancer that arises from cells of the salivary and other glands and is characterized by high invasiveness.
- What are the main symptoms of EMC? Painless swelling in the area of the salivary glands, possible swelling and discomfort.
- Which doctor should I contact if I suspect I have this disease? It is recommended to consult an oncologist or a specialist in salivary gland diseases.
- How is EMC treated? Treatment includes surgery, chemotherapy and radiation therapy.
- What is the prognosis for epithelial-myoepithelial carcinoma? If detected early, treatment can be effective and five-year survival rates can exceed 70%.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends paying attention to any changes in the body and not ignoring symptoms such as formations in the salivary glands or long-term discomfort. Regular medical examinations and early diagnostics can significantly increase the chances of successful treatment. Also, at each stage, support from specialists and professional support during the therapy process are important.
